Lateral flow is a flexible and rapid platform for companion diagnostics, offering time, cost and usability efficiencies. This is the message which the BBI Group will be taking to this year’s BIO - June 18th to 21st 2012, Boston.
Commenting on BBI’s attendance at the show this year, Dr Pete Corish, Head of Innovation at BBI, highlights the growing importance for pharma companies to have a diagnostic partner in place for successful, rapid drug development.
"We have strong relationships with some of the world’s largest diagnostic companies who understand that collaborative strategic planning is essential from project initiation stages. This important factor should be incorporated into product development by pharma companies when utilising a companion diagnostic - launch delays will be eliminated and it will be ensured that full potential of the diagnostic is realised," commented Pete.
"We strongly believe that the partnership approach taken by BBI within development projects is fundamental to the success of the product and its impact on the market place. BIO will be a valuable opportunity to explore potential diagnostic-pharma collaborations; in particular BBI will be showcasing the vital benefits which lateral flow offers the pharma market and the impact these have on patient care and the all-important objective of personalised medicine."
BBI has been a trusted partner to some of the world’s leading diagnostic companies for over 25 years. Founded upon the success of the superior quality and performance of their gold reagents, the company has grown to be a world leader offering end to end, fully flexible products and services for IVD assay development.
The BBI Group can now assist in all stages supplying everything from immunoassay reagents including enzymes, antibodies and antigens, nanoparticle labels and patient samples, right through to offering fully customised assay development and contract manufacturing services.